全文获取类型
| 收费全文 | 21699篇 |
| 免费 | 1281篇 |
| 国内免费 | 161篇 |
专业分类
| 耳鼻咽喉 | 245篇 |
| 儿科学 | 561篇 |
| 妇产科学 | 727篇 |
| 基础医学 | 2375篇 |
| 口腔科学 | 629篇 |
| 临床医学 | 1736篇 |
| 内科学 | 4318篇 |
| 皮肤病学 | 476篇 |
| 神经病学 | 959篇 |
| 特种医学 | 864篇 |
| 外国民族医学 | 14篇 |
| 外科学 | 3939篇 |
| 综合类 | 413篇 |
| 现状与发展 | 2篇 |
| 一般理论 | 12篇 |
| 预防医学 | 1837篇 |
| 眼科学 | 608篇 |
| 药学 | 1983篇 |
| 中国医学 | 150篇 |
| 肿瘤学 | 1293篇 |
出版年
| 2023年 | 240篇 |
| 2022年 | 720篇 |
| 2021年 | 1288篇 |
| 2020年 | 687篇 |
| 2019年 | 863篇 |
| 2018年 | 1143篇 |
| 2017年 | 668篇 |
| 2016年 | 723篇 |
| 2015年 | 742篇 |
| 2014年 | 1041篇 |
| 2013年 | 1201篇 |
| 2012年 | 1736篇 |
| 2011年 | 1920篇 |
| 2010年 | 1095篇 |
| 2009年 | 816篇 |
| 2008年 | 1135篇 |
| 2007年 | 1152篇 |
| 2006年 | 1045篇 |
| 2005年 | 977篇 |
| 2004年 | 846篇 |
| 2003年 | 799篇 |
| 2002年 | 696篇 |
| 2001年 | 159篇 |
| 2000年 | 133篇 |
| 1999年 | 116篇 |
| 1998年 | 85篇 |
| 1997年 | 78篇 |
| 1996年 | 84篇 |
| 1995年 | 69篇 |
| 1994年 | 62篇 |
| 1993年 | 52篇 |
| 1992年 | 51篇 |
| 1991年 | 59篇 |
| 1990年 | 58篇 |
| 1989年 | 48篇 |
| 1988年 | 53篇 |
| 1987年 | 49篇 |
| 1986年 | 40篇 |
| 1985年 | 38篇 |
| 1984年 | 43篇 |
| 1983年 | 36篇 |
| 1982年 | 34篇 |
| 1981年 | 24篇 |
| 1980年 | 22篇 |
| 1978年 | 17篇 |
| 1977年 | 15篇 |
| 1976年 | 24篇 |
| 1974年 | 14篇 |
| 1973年 | 25篇 |
| 1966年 | 13篇 |
排序方式： 共有10000条查询结果，搜索用时 890 毫秒
1.
2.
3.
4.
Khaled Adil Marija Popovic Fabio L. Cury Sergio L. Faria Marie Duclos Luis Souhami 《Practical radiation oncology》2019,9(1):24-28
Purpose
This study aimed to investigate 3 planning target volume (PTV) margin expansions and determine the most appropriate volume to be used in bladder preservation therapy when using daily cone beam computed tomography (CBCT). We aimed to establish whether a smaller PTV expansion is feasible without risking geographical miss.Methods and materials
The study included patients with bladder cancer who were treated with a hypofractionated course of radiation therapy delivered with intensity modulated radiation therapy. The clinical target volume (CTV) was the whole empty bladder, and the PTV consisted of a 1.5-cm margin around the bladder (PTV1.5 cm). Patients underwent daily CBCT imaging before treatment to assess the bladder volume and ensure accurate positioning. We investigated 2 additional smaller PTV margin expansions to determine the most appropriate volume to be used with CBCT as a daily image guided radiation therapy modality. These margins were created retrospectively on every CBCT. The first additional volume was a uniform PTV margin of the surrounding 1 cm (PTV1 cm). When considering that the majority of the internal bladder movement was due to the variation in filling that occurs in the superior and anterior directions, a second volume of an anisotropic PTV margin with a 1.5-cm superior/anterior and 1 cm in other directions (PTV1/1.5 cm) was created. We recorded the frequency and measured the volume of bladder falling out of each PTV based on the daily CBCT.Results
For the purpose of this study, we considered an arbitrary 5 cm3 of CTV falling out of the designated PTV as a clinically significant volumetric miss. The frequency of such a miss when applying the uniform PTV1 cm was 1%. However, when applying the uniform PTV1.5 cm and anisotropic PTV1/1.5 cm margins, the frequency was 0.5% and 0.5%, respectively.Conclusions
The anisotropic PTV expansion of 1.5 cm superiorly and anteriorly and 1 cm in all other directions around the bladder (CTV) provides a safe PTV approach when daily CBCT imaging is used to localize an empty bladder. 相似文献5.
6.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献7.
8.
9.
10.
Introduction: Cutaneous T-cell lymphomas (CTCL) are rare non-Hodgkin lymphomas of skin-homing T-cells that initially or mainly manifest cutaneously. Treatment of CTCL is challenging given the disease states’ varying presentation and prognosis. Systemic treatment options often lack comparative evidence and have relatively low response rates and short duration of response. The recent Food and Drug Administration (FDA) approval of mogamulizumab in adult patients with relapsed or refractory (R/R) CTCL after at least one prior line of therapy provided a new treatment option to patients with advanced disease.
Areas covered: The authors discuss basic information about CTCL and mogamulizumab’s mechanism of action. Then, the authors discuss the agent’s efficacy. Finally, the authors evaluate the safety of mogamulizumab in comparison to other agents available in CTCL.
Expert opinion: Mogamulizumab has been shown to be an effective and well tolerated therapy for patients with relapsed and refractory MF/SS with excellent activity in the circulating component of the disease. 相似文献